Tag Directory / CANCERRESEARCH     showing 1–12 of 12



Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma / ESMO

esmo - Findings from the ZSAB-neoGOLP study

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch #clinicaltrials


Monday, March 16, 2026, 3:21 am / permalink 20797 / 3 stories in 15 hrs


NRG-LU005 Trial: Atezolizumab Plus Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer / OncoDaily

oncodaily - A major international clinical trial, NRG-LU005, has provided important new insight into how immunotherapy should be used in limited-stage small cell lung cancer (SCLC). While immune checkpoint inhibitors have significantly […]

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch


Monday, March 16, 2026, 12:23 am / permalink 20789 / 4 stories in 18 hrs


A new triple negative breast cancer target: Why HORMAD1 could guide treatment choices / Medical Express

medicalxpress - A gene that is typically active only in reproductive cells may hold the key to new treatments for triple negative breast cancer, according to new research published in the journal Nature Communications. Scientists from the Breast Cancer Now Toby Robins Re…

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch


Saturday, March 14, 2026, 11:21 pm / permalink 20776 / 4 stories in 43 hrs


Roche’s big hope breast cancer drug fails in crucial first-line trial / Endpoints

Elizabeth Cairns / endpoints - Roche’s breast cancer pill, which the company recently said had the potential to become its biggest-ever selling drug, has failed in what is arguably its most important Phase 3 trial. The persevERA ...

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch


Saturday, March 14, 2026, 7:21 pm / permalink 20770 / 5 stories in 47 hrs


Fitch upgrades UCHealth’s rating to ‘AA+’ / Beckers

Andrew Cass / beckershospitalreview - Aurora, Colo.-based UCHealth’s credit rating was upgraded to “AA+” from “AA” by Fitch. The upgrade reflects the health system’s very strong financial profile, benefiting from its market position in a growing service area and a long track record of robust …

#healthcare #publichealth #governmentpolicy #digitalhealth #medicaldevices #oncology #hospitaloperations #cancerresearch


Saturday, March 14, 2026, 2:22 pm / permalink 20762 / 5 stories in 2 days


Antonio Calles: RECITE Trial Findings on Romiplostim for Chemotherapy-Induced Thrombocytopenia / OncoDaily

oncodaily - Antonio Calles, Medical Oncologist at Hospital General Universitario Gregorio Marañón and faculty member of the Lung and Other Thoracic Tumours faculty group of the ESMO, shared a post by NEJM, […]

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch


Saturday, March 14, 2026, 12:23 pm / permalink 20760 / 2 stories in 2 days


Personalized Support Program Improves Smoking Cessation for Cervical Cancer Survivors – UCLA Health / OncoDaily

oncodaily - UCLA study shows program doubles quit rates for women and offers a cost-effective approach A new study led by UCLA researchers suggests that a personalized counseling program can significantly help […]

#healthcare #publichealth #oncology #behavioralhealth #cancerresearch


Saturday, March 14, 2026, 6:21 am / permalink 20747 / 2 stories in 2 days


Grail names new CEO as Bob Ragusa retires / Endpoints

Jared Whitlock / endpoints - Grail on Thursday announced that its CEO, Bob Ragusa, will retire and is handing the reins to its current president Josh Ofman. The cancer screening company said the move was the culmination of long-term succession ...

#healthcare #biotech #medicaldevices #oncology #healthcarefinance #cancerresearch


Saturday, March 14, 2026, 4:21 am / permalink 20744 / 5 stories in 2 days


Ipsen pulls cancer drug Tazverik from market over safety risks / Endpoints

Nicole DeFeudis / endpoints - Ipsen is pulling its cancer drug Tazverik from the market after an independent data monitoring committee found safety concerns in a confirmatory trial. The committee reported cases of secondary cancers that begin in blood-forming tissue ...

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda #productrecall #oncology #cancerresearch


Saturday, March 14, 2026, 12:23 am / permalink 20738 / 3 stories in 2 days


Severe COVID or Severe Flu May Raise Risk of Lung Cancer, But Vaccines Helped in Animal Tests / Discover

discovermagazine - Learn how severe respiratory illness leaves the lungs vulnerable to cancer, and how vaccines could prevent these vulnerabilities.

#healthcare #publichealth #vaccinesafety #oncology #animalhealth #infectiousdisease #cancerresearch


Friday, March 13, 2026, 9:23 pm / permalink 20726 / 3 stories in 2 days


Engineering CAR T cells to secrete VEGF-neutralizing scFvs enhances antitumor activity against solid tumors / Science Translational Medecine

Torahito A. Gao, Ryan M. Shih, Justin D. Clubb, Shao-Hsi Hung, Tanya Singh, Laura B. James-Allan, Ga / science - Science Translational Medicine, Volume 18, Issue 839, March 2026.

#pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch


Monday, March 9, 2026, 4:22 am / permalink 20364 / 18 stories in 7 days


Elizabeth McKenna: New Cancer Grand Challenges Teams Announced / OncoDaily

oncodaily - Elizabeth McKenna, Executive Editor of Cancer Discovery, shared a post on X: “The new Cancer Grand Challenges teams have just been announced! Read about the teams tackling cancer avoidance, mechanisms […]

#healthcare #biotech #drugdevelopment #oncology #healthcarefinance #cancerresearch #researchfunding


Saturday, March 7, 2026, 11:22 am / permalink 20326 / 81 stories in 9 days


Back to Top


CANCERRESEARCH Heatmap


90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.



More Top Stories...


FDA refuses to review Moderna mRNA flu vaccine application

Moderna’s mRNA flu vaccine application has been rejected by the FDA—Moderna received a refusal‐to‐file letter while accusing the agency of shifting its review standards. Multiple reports echo this regulatory setback, fueling industry concerns over consistent, transparent decision‐making. More...


FDA CRL halts AstraZeneca’s Saphnelo prefilled pen approval

AstraZeneca’s application to market its subcutaneous prefilled pen formulation of Saphnelo for treating lupus has hit a roadblock after the FDA issued a complete response letter. The decision delays the drug’s approval and raises questions about its future in the competitive immunotherapy market. More...


CMS proposes sweeping changes to ACA marketplace plan rules

CMS has proposed a major rule reshaping Affordable Care Act marketplace policies, including loosening limits on non-standard plan designs and promoting lower-premium options such as catastrophic coverage. The agency says the changes will reduce costs and boost flexibility, while critics warn they could increase confusion and weaken consumer protections—because shopping for insurance clearly wasn’t complicated enough. More...


Tenet forecasts major ACA exchange enrollment drop and financial hit

Tenet Healthcare is warning that the expiration of enhanced Affordable Care Act premium tax credits will drive a steep reduction in ACA exchange enrollment, projecting a significant revenue impact in 2026. Despite the headwind, the company says it expects earnings growth, leaning on acuity and operational performance—because nothing calms Wall Street like “we’ll make it up somewhere else.” More...


City of Hope promotes Nisha Morris to senior marketing chief

City of Hope named Nisha Morris as Senior Vice President and Chief Marketing and Communications Officer, adding marketing leadership to its executive team. The move signals a renewed focus on brand, outreach, and patient engagement as the cancer center sharpens its communication and growth strategies. More...



NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.